BML Investment Partners, L.P. 13D and 13G filings for AN2 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-30 5:46 pm Sale |
2025-05-28 | 13D | AN2 Therapeutics, Inc. ANTX |
BML Investment Partners, L.P. | 3,217,423 10.700% |
-2,532,009 (-44.04%) |
Filing |
| 2025-05-07 10:27 am Unchanged |
2025-05-07 | 13D | AN2 Therapeutics, Inc. ANTX |
BML Investment Partners, L.P. | 5,749,432 19.100% |
0 (Unchanged) |
Filing |
| 2025-02-13 4:28 pm Unchanged |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
BML Investment Partners, L.P. | 5,749,432 19.200% |
0 (Unchanged) |
Filing |
| 2024-08-14 9:00 pm Purchase |
2024-08-14 | 13G | AN2 Therapeutics, Inc. ANTX |
BML Investment Partners, L.P. | 5,749,432 19.300% |
1,500,000 (+35.30%) |
Filing |
| 2024-08-12 4:48 pm Purchase |
2024-08-09 | 13G | AN2 Therapeutics, Inc. ANTX |
BML Investment Partners, L.P. | 4,249,432 14.200% |
4,249,432 (New Position) |
Filing |